See more : Great Western Mining Corporation PLC (8GW.IR) Income Statement Analysis – Financial Results
Complete financial analysis of Zomedica Corp. (ZOM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zomedica Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Future Health ESG Corp. (FHLTW) Income Statement Analysis – Financial Results
- New World Resources Limited (NWC.AX) Income Statement Analysis – Financial Results
- TDSE Inc. (7046.T) Income Statement Analysis – Financial Results
- FLEX LNG Ltd. (0RQ8.L) Income Statement Analysis – Financial Results
- Plastec Technologies, Ltd. (PLTYF) Income Statement Analysis – Financial Results
Zomedica Corp. (ZOM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zomedica.com
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.19M | 18.93M | 4.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.87M | 5.28M | 1.08M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.32M | 13.65M | 3.05M | -530.02K | -787.61K | -205.77K | -92.41K | -45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 68.76% | 72.12% | 73.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.74M | 2.58M | 1.67M | 8.04M | 10.35M | 10.32M | 2.75M | 1.52M | 758.05K | 0.00 | 0.00 |
| General & Administrative | 29.03M | 22.93M | 0.00 | 7.93M | 8.18M | 5.83M | 5.08M | 4.24M | 1.43M | 42.41K | 77.50K |
| Selling & Marketing | 14.14M | 9.88M | 0.00 | 261.91K | 471.89K | 225.89K | 164.25K | 194.19K | 143.47K | 0.00 | 0.00 |
| SG&A | 43.17M | 33.00M | 22.75M | 8.19M | 8.65M | 6.06M | 5.24M | 4.43M | 1.57M | 42.41K | 77.50K |
| Other Expenses | 0.00 | -7.00K | 6.00K | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.91M | 35.58M | 24.43M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Cost & Expenses | 56.78M | 40.85M | 25.51M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Interest Income | 5.46M | 2.70M | 357.45K | 32.86K | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 175.00K | 1.00K | 6.05K | 732.00 | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.30M | 4.04M | 1.14M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 9.05K | 0.00 | 0.00 |
| EBITDA | -29.39M | -15.34M | -19.57M | -16.38M | -19.00M | -16.44M | -7.97M | -5.97M | -2.28M | -42.41K | -77.50K |
| EBITDA Ratio | -116.68% | -80.23% | -479.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.59M | -21.92M | -21.37M | -16.76M | -19.78M | -16.58M | -8.08M | -6.00M | -2.29M | -42.41K | -77.50K |
| Operating Income Ratio | -125.43% | -115.81% | -517.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.27M | 2.54M | 657.78K | -146.81K | 273.00 | -68.44K | 18.98K | 258.06K | 7.44K | 0.00 | 0.00 |
| Income Before Tax | -35.86M | -19.38M | -20.72M | -16.91M | -19.78M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Income Before Tax Ratio | -142.38% | -102.38% | -501.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.33M | -2.37M | -2.33M | 9.33K | 38.08K | 136.88K | -18.98K | 28.59K | 0.00 | 0.00 | 0.00 |
| Net Income | -34.53M | -17.02M | -18.38M | -16.92M | -19.82M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Net Income Ratio | -137.10% | -89.88% | -444.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| EPS Diluted | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| Weighted Avg Shares Out | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 92.49M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
| Weighted Avg Shares Out (Dil) | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 93.44M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting...
3 Hidden-Gem Penny Stocks That Could Yield Life-Changing Wealth
In stock market investments, identifying hidden gems can be the key to unlocking extraordinary wealth. It's akin to discovering a treasure trove — a gateway to unprecedented wealth and financial transformation.
Open Letter to Zomedica Shareholders from your Chief Executive Officer
ANN ARBOR, MI / ACCESSWIRE / January 31, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Chief Executive Officer Larry...
Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference
ANN ARBOR, MI / ACCESSWIRE / January 30, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive...
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split
ANN ARBOR, MI / ACCESSWIRE / January 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Institutional Shareholder Services ("ISS"),...
Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")
ANN ARBOR, MI / ACCESSWIRE / January 17, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today provided a business update and will...
3 Breakout Penny Stocks Primed for Massive Gains
In the volatile space of penny stocks, three companies are emerging as powerhouses with breakout potential, poised for massive gains. To begin with, the first one's organic growth, the second one's data licensing prowess in liquor retail, and the third...
Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Shareholders on February 28, 2024
ANN ARBOR, MI / ACCESSWIRE / January 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting...
Budget Bets: Top 3 Penny Stocks with Potential for Explosive Growth
Penny stocks are presenting as attractive buys right now as the valuations of larger-cap firms continue to stretch. The price-to-earnings (P/E) ratio of the S&P 500, for example, sits at 24.59x earnings, roughly in line with its long-term average.
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
ANN ARBOR, MI / ACCESSWIRE / January 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of an article...
Source: https://incomestatements.info
Category: Stock Reports
How has Zomedica’s diagnostic product revenue grown?
Zomedica (NYSE:ZOM) reported Q3 2024 financial results with revenue growing 10% to $7.0 million, maintaining a strong gross margin of 72.3%. The Diagnostics segment grew 38%, while the Therapeutic Device segment increased 9%.
What were Zomedica’s revenue and losses in the last 12 months?
In the last 12 months, Zomedica had revenue of $26.73 million and -$62.19 million in losses. Loss per share was -$0.06.